Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

20.25 -1.38 (-6.36%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,325,511
Open 21.45
Bid (Size) 20.24 (4,000)
Ask (Size) 20.25 (800)
Prev. Close 21.62
Today's Range 20.21 - 21.63
52wk Range 1.720 - 28.41
Shares Outstanding 88,406,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+126.7%
+126.7%
1 Month
-27.1%
-27.1%
3 Month
+63.9%
+63.9%
6 Month
+127.5%
+127.5%
1 Year
+971.2%
+971.2%

More News

Read More
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
A Peek at Tango Therapeutics's Future Earnings ↗
Via Benzinga
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
From Equity Insider
Via GlobeNewswire
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
Via MarketMinute
Topics Intellectual Property
News headline image
TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction ↗
Via Chartmill
Topics Earnings
News headline image
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Tango Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tango Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tango Therapeutics, Inc. - Common Stock trade on?
Tango Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tango Therapeutics, Inc. - Common Stock?
The ticker symbol for Tango Therapeutics, Inc. - Common Stock is TNGX on the Nasdaq Stock Market
What is the current price of Tango Therapeutics, Inc. - Common Stock?
The current price of Tango Therapeutics, Inc. - Common Stock is 20.25
When was Tango Therapeutics, Inc. - Common Stock last traded?
The last trade of Tango Therapeutics, Inc. - Common Stock was at 05/22/26 03:58 PM ET
What is the market capitalization of Tango Therapeutics, Inc. - Common Stock?
The market capitalization of Tango Therapeutics, Inc. - Common Stock is 1.79B
How many shares of Tango Therapeutics, Inc. - Common Stock are outstanding?
Tango Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.